US4900558A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release ibuprofen formulation including a core of ibuprofen and a microcrystalline cellulose and a covering of acrylic polymer and hydroxylated cellulose derivative
Assignee: BIOSAT Ltd
•
Filing: 1987-07-30
•
Granted: 1990-02-13
•
Expires: 2007-07-30
Abstract
Abstract The present invention provides a sustained release αmethyl-4-(2-methylpropyl)benzene acetic acid (Ibuprofen) formulation comprising sufficient granules to provide a predetermined dose or number of doses of Ibuprofen, each granule having a diameter between 0.5 and 2.0 mm and comprising: (a) a core containing 100 parts of Ibuprofen and from 10 to 70 parts of a microcrystalline cellulose; and (b) a coating covering substantially the whole surface of the core and comprising 100 parts of a water insoluble but water swellable acrylic polymer and 20 to 70 parts of a water-soluble hydroxylated cellulose derivative, the weight of the coating being from 5 to 20% of the weight of the core.
Inventors
- 👤 Brian W. Barry
- 👤 Bryan A. Mulley
- 👤 Peter York
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 08:57
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5026; A61K9/5036; A61K9/5042; A61K9/5047; A61P; A61P25/00; A61P25/04; A61P29/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
103 words
A sustained release α-methyl-4-(2-methylpropyl)benzene acetic acid (Ibuprofen) formulation comprising sufficient granules to provide a dose or number of doses of Ibuprofen, each granule having a diameter between 0.5 and 2.0 mm and comprising: (a) a core containing 100 parts of Ibuprofen and from 10 to 70 parts of a microcrystalline cellulose; and (b) a coating covering substantially the whole surface of the core and comprising 100 parts of a water insoluble but water swellable acrylic polymer and 20 to 70 parts of a water-soluble hydroxylated cellulose derivative, the weight of the coating being from 5 to 20% of the weight of the core.
Claim 2
Dependent Claim
103 words
A sustained release α-methyl-4-(2-methylpropyl)benzene acetic acid (Ibuprofen) formulation comprising sufficient granules to provide a dose or number of doses of Ibuprofen, each granule having a diameter between 0.5 and 2.0 mm and comprising: (a) a core containing 100 parts of Ibuprofen and from 10 to 70 parts of a microcrystalline cellulose; and (b) a coating covering substantially the whole surface of the core and comprising 100 parts of a water insoluble but water swellable acrylic polymer and 20 to 70 parts of a water-soluble hydroxylated cellulose derivative, the weight of the coating being from 5 to 20% of the weight of the core.
Claim 3
Dependent Claim
50 words
The formulation of claim 1, which is a 24 hour formulation, wherein the granule diameter is between 1.5 and 2.0 mm, the coating contains 25 to 35 parts of the water soluble hydroxylated cellulose derivative, and the weight of the coating is approximately 20% of the weight of the core.
Claim 4
Dependent Claim
52 words
The formulation of claim 1, which is a 12 hour formulation, wherein the granule diameter is between 0.7 and 1.2 mm, the coating contains 25 to 35 parts of the water soluble hydroxylated cellulose derivative, and the weight of the coating is between 8 and 12% of the weight of the core.
Claim 5
Dependent Claim
18 words
The formulation of claim 1, wherein the core contains between 15 and 20 parts of the microcrystalline cellulose.
Claim 6
Dependent Claim
17 words
The formulation of claim 1, wherein the coating comprises about 30 parts of the hydroxylated cellulose derivative.
Claim 7
Dependent Claim
32 words
The formulation of claim 1, wherein the hydroxylated cellulose derivative is hydroxypropyl methycellulose having a degree of substitution of 28 to 30% of methoxy groups and 7 to 12% of hydroxy groups.
Claim 8
Dependent Claim
11 words
The formulation of claim 1, wherein the acrylic polymer is neutral
Claim 9
Dependent Claim
13 words
The formulation of claim 1, wherein the granules are contained in a capsule.
Claim 10
Dependent Claim
50 words
A process for producing a formulation according to claim 1 comprising: 1. mixing the Ibuprofen with the microcrystalline cellulose; 2. forming the mixture into particles; 3. forming a solution of the hydroxylated cellulose derivative and the acrylic polymer and 4. coating the particles using the solution to form the granules.
Claim 11
Dependent Claim
12 words
The process of claim 9, wherein the granules are sieved after formation.
References Cited (Backward Citations)
US4138475A
Cited
US4578264A
Cited
US4205060A
Cited
US4343789A
Cited
US4555399A
Cited
US4695591A
Cited
US4710384A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-12 | 1993-08-14 | 1994-02-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-12 | 1997-08-14 | 1998-02-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-12 | 2001-08-14 | 2002-02-13 | $7700.00 | Window Closed / Lapsed |